Hester Biosciences Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016
January 19, 2017 at 12:53 am EST
Share
Hester Biosciences Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported net sales/income from operations of INR 285.23 million compared to INR 241.77 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 81.53 million compared to INR 62.66 million a year ago. Net profit from ordinary activities after tax was INR 58.01 million or INR 6.82 per basic and diluted share before and after extraordinary items not annualized compared to INR 47.58 million or INR 5.59 per basic and diluted share before and after extraordinary items not annualized a year ago. The company has invested INR 61.9 million as a capex.
For the nine months, the company reported net sales/income from operations of INR 882.85 million compared to INR 727.11 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 254.25 million compared to INR 192.60 million a year ago. Net profit from ordinary activities after tax was INR 177.68 million or INR 20.89 per basic and diluted share before and after extraordinary items not annualized compared to INR 137.18 million or INR 16.13 per basic and diluted share before and after extraordinary items not annualized a year ago. The total investment in capex stands at INR 112.7 million.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.